Ads
related to: telomerase for cancer treatment procedure- Dosing & Administration
Healthcare Professionals: See How
Your Patients May Receive Treatment
- Identifying Patients
Discover Patient Identification &
IHC Info. Will You Take Action?
- Official Physician Site
Visit Site For A Treatment
Option For Metastatic Solid Tumors.
- Mechanism Of Action
MOA For A Therapy In Multiple
Metastatic Solid Tumor Types.
- Access Data & Results
View Data To See If A Treatment For
Metastatic Solid Tumors May Help.
- Request A Contact
Complete A Brief Form To Receive
Updates For A Treatment Option.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
It must be combined with surgery, radiation, chemotherapy or immunotherapy. [57] Cells may reduce their telomere length by only 50-252 base pairs per cell division, which can lead to a long lag phase. [59] [60] A telomerase activator TA-65 is commercially available and is claimed to delay aging and to provide relief from certain disease conditions.
Two concerns with applying telomerase inhibitors in cancer treatment are that effective treatment requires continuous, long-term drug application and that off-target effects are common. [30] For example, the telomerase inhibitor imetelstat, first proposed in 2003, [31] [32] has been held up in clinical trials due to hematological toxicity. [30]
Alternative Lengthening of Telomeres (also known as "ALT") is a telomerase-independent mechanism by which cancer cells avoid the degradation of telomeres.. At each end of the chromosomes of most eukaryotic cells, there is a telomere: a region of repetitive nucleotide sequences which protects the end of the chromosome from deterioration or from fusion with neighboring chromosomes.
90% of cancers are characterized by increased telomerase activity. [28] Lung cancer is the most well characterized type of cancer associated with telomerase. [29] There is a lack of substantial telomerase activity in some cell types such as primary human fibroblasts, which become senescent after about 30–50 population doublings. [28]
HeLa cells are rapidly dividing cancer cells, and the number of chromosomes varies during cancer formation and cell culture. The current estimate (excluding very tiny fragments) is a "hypertriploid chromosome number (3n+)", which means 76 to 80 total chromosomes (rather than the normal diploid number of 46) with 22–25 clonally abnormal ...
Medical research for cancer begins much like research for any disease. In organized studies of new treatments for cancer, the pre-clinical development of drugs, devices, and techniques begins in laboratories, either with isolated cells or in small animals, most commonly rats or mice. In other cases, the proposed treatment for cancer is already ...